PRRSV recombinant antigen A1 inhibits the expression of CD163 on the cell surface by inducing the polarization of M1 macrophage subset, which can further effectively reduce virus invasionreduce infection. A1 can regulate the endogenous genes of alveolar macrophages to activate Th1-type immune responseenhance cellular immunity. Therefore, this technical invention will be beneficial to screen the new generation of PSSRV candidate structural vaccines.

Two COVID-19 animal models, including humanized Ace2 micehuman peripheral blood lymphocyte transplanted mice, are used to mimic COVID-19 infection, immune responsecytokine release syndrome in human. The immune analytical platform can further outline the immune cell, cytokinebiomarker response pattern after viral infection. The COVID-19 humanized animal modelthe immune analytical platform will support COVID-19 related researchfacilitate new drugnew therapy validation.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.

In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.